

April 2, 2024

The Listing Department BSE Limited Phiroze Jeejebhoy Towers, Dalal Street, Fort, Mumbai – 400001 BSE Scrip Code: 543427 The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform that one of the subsidiary of the Company i.e., Optival Health Solutions Private Limited has received a suspension order from Drugs and Control authorities under Drugs and Cosmetic Act, 1940 and Drugs and Cosmetics Rules, 1945 temporarily suspending the operations pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 details are provided below:

Name(s) of the Authority:	Nature and details of the action(s) taken, initiated or order(s) passed	Date of receipt of direction or order, including any adinterim or interim orders, or any other communication from the authority	violation(s) / contravention(s) committed or alleged	Impact on financial operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
Assistant Director	Temporary suspension	Order received on	Under Rule 65(2),	Potential Revenue
Drugs Control	of Drug License for five	01.04.2024	65(4)(3)(ii), 65(9)(a)	Loss of Rs~ 3.29 Lacs.
Administration,	days of a store situated		under the Drug and	
Hanamkonda	at NGOS Colony		Cosmetic Act 1940	
Telangana	Hanamkonda,		and Rules 1945	
	Telangana			

The Company is reviewing the aforesaid order and evaluating the next steps in this matter.

Kindly take the same on records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava Company Secretary FCS 7460